Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4470187

CCN(CC)Cc1ccc(NC(=O)c2cc3cc(OCc4ccc(Cl)nc4)ccc3[nH]2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
RXFP1 Q9HBX9 2/20 0.43
PYGL P06737 5/20 0.42
NHERF1 O14745 2/20 0.42
TP53 P04637 1/20 0.41
ALDH1A1 P00352 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
SRD5A2 P31213 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PRNP P04156 1/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
FLT3 P36888 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13864592 0.94 NPC1 (0.48) KDM4ENPC1RAB9ARXFP1PYGL
Trifluoroacetic Acid SCHEMBL4466678 0.85 KDM4E (0.45) KDM4ENPC1RAB9ARXFP1PYGL
Trifluoroacetic Acid SCHEMBL4474971 0.85 KDM4E (0.46) KDM4ENPC1RAB9ARXFP1PYGL
SCHEMBL4470405 0.84 PYGL (0.48) KDM4ENPC1RAB9ARXFP1PYGL
SCHEMBL4460803 0.83 KDM4E (0.59) KDM4ENPC1RAB9ARXFP1TP53
SCHEMBL13864623 0.82 KDM4E (0.48) KDM4ENPC1RAB9ARXFP1PYGL
SCHEMBL4467264 0.82 PYGL (0.50) KDM4ENPC1RAB9ARXFP1PYGL
Trifluoroacetic Acid SCHEMBL4473783 0.81 KDM4E (0.55) KDM4ENPC1RAB9ARXFP1PYGL
SCHEMBL4470196 0.80 ALDH1A1 (0.40) KDM4ENPC1RAB9ATP53ALDH1A1
Trifluoroacetic Acid SCHEMBL4461643 0.79 KDM4E (0.52) KDM4ENPC1RAB9ARXFP1PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7531668-B2 2-arylcarboxamide-nitrogenous heterocycle compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-05-12 US disclosed
US-20070299070-A1 2-Arylcarboxamide-Nitrogenous Heterocycle Compound MSD K.K. (JP) 2007-12-27 US disclosed
EP-1798221-A1 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299070-A1 2-Arylcarboxamide-Nitrogenous Heterocycle Compound MCHR2, MCHR1, NPY2R KDM4E 2454/4885NPC1 864/4885RAB9A 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.